Skip to main content Accessibility help
×
Hostname: page-component-74656f9884-6grmk Total loading time: 0 Render date: 2026-11-04T06:12:28.624Z Has data issue: false hasContentIssue false

Chapter 5 - Recreational Drugs Repurposed for Medicinal Use – Cannabis

Published online by Cambridge University Press:  24 July 2026

By
Mike Armour ,
Justin Sinclair  and
Hannah Adler
Edited by
Seetal Dodd ,
Michael Berk  and
Stephen M. Stahl
Seetal Dodd
Affiliation:
Deakin University, Melbourne
Michael Berk
Affiliation:
Deakin University, Melbourne
Stephen M. Stahl
Affiliation:
University of California, Riverside
Get access

Summary

Cannabis has a long history as a medicine and was a part of medical practice until the late nineteenth century. The discovery of cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) in the mid-twentieth century, and then the various components of the endocannabinoid system (ECS) over the following decades have again brought cannabis back into the public eye as a potential therapeutic agent. At present, cannabis is being used for both recreational and medical purposes. Evidence for cannabis as a medicine is still an emerging field, and while potential mechanisms of action for a variety of conditions have been elucidated, including cancer, epilepsy, and chronic pain, high-quality randomized controlled trials in humans are still lacking.

Despite popular beliefs, cannabis, like all other medicines, has potential benefits and harms, and long-term consumption of cannabis, even for medical reasons, may not be risk-free. In addition, consumption via modes of administration such as smoking or using a bong may increase the risk of negative health outcomes.

Keywords

cannabispaininflammationcannabinoidendocannabinoidcannabidioltetrahydrocannabinolmarijuana

Information

Type
Chapter
Information
Recreational Drugs Repurposed for Medicinal Use , pp. 82 - 111
Publisher: Cambridge University Press
Print publication year: 2026

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

McPartland, JM. Cannabis systematics at the levels of family, genus, and species. Cannabis Cannabinoid Res. 2018;3(1):203–212.CrossRefGoogle ScholarPubMed
Sinclair, J. The endocannabinoid system and cannabis. In Hechtman, L, ed. Advanced Clinical Naturopathic Medicine. St. Louis, MO: Elsevier Health Sciences; 2020: chapter 20, 795–822.Google Scholar
Karki, P, Rangaswamy, M. A review of historical context and current research on cannabis use in India. Indian J Psychol Med. 2022;45(2):105–116.CrossRefGoogle ScholarPubMed
Small, E, Cronquist, A. A practical and natural taxonomy for Cannabis. Taxon. 1976;25:405–435.CrossRefGoogle Scholar
Upton, R, ElSohly, M, Romm, A, Russo, E, Sexton, M, eds. Cannabis Inflorescence. Scotts Valley, CA: American Herbal Pharmacopoeia; 2013.Google Scholar
Tanney, CAS, Backer, R, Geitmann, A, Smith, DL. Cannabis glandular trichomes: a cellular metabolite factory. Front Plant Sci. 2021;12:721986.CrossRefGoogle ScholarPubMed
Wang, X, Shen, C, Meng, P, Tan, G, Lv, L. Analysis and review of trichomes in plants. BMC Plant Biol. 2021;21(1):70.CrossRefGoogle ScholarPubMed
Kovalchuk, I, Pellino, M, Rigault, P, et al. The genomics of cannabis and its close relatives. Annu Rev Plant Biol. 2020;71:713–739.CrossRefGoogle ScholarPubMed
Russo, EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344–1364.CrossRefGoogle ScholarPubMed
Zandkarimi, F, Decatur, J, Casali, J, et al. Comparison of the cannabinoid and terpene profiles in commercial cannabis from natural and artificial cultivation. Molecules. 2023;28(2):833. doi:10.3390/molecules28020833. PMID: 36677891; PMCID: PMC9861703.CrossRefGoogle ScholarPubMed
Kalant, H. Medicinal use of cannabis: history and current status. Pain Res Manag. 2001;6(2):80–91.CrossRefGoogle ScholarPubMed
Pisanti, S, Bifulco, M. Medical cannabis: a plurimillennial history of an evergreen. J Cell Physiol. 2019;234(6):8342–8351.CrossRefGoogle ScholarPubMed
Ben Amar, M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol. 2006;105(1–2):1–25.CrossRefGoogle Scholar
Frankhauser, M. History of cannabis in Western medicine. In Russo, EB, ed. Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. New York: Hamworth Integrative Healing Press; 2002:37–51.Google Scholar
Li, H-L. An archaeological and historical account of cannabis in China. Econ Bot. 1974;28(4):437–448.CrossRefGoogle Scholar
Warf, B. High points: an historical geography of cannabis. Geogr Rev. 2014;104(4):414–438.CrossRefGoogle Scholar
Crocq, M-A. History of cannabis and the endocannabinoid system. Dialogues Clin Neurosci. 2020;22(3):223–228.CrossRefGoogle ScholarPubMed
Sinclair, J. The Ethnopharmacology of Cannabis: From the Neolithic to Now. Hemp Health & Innovation Expo; 2018.Google Scholar
Baron, EP. Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it’s been … Headache: J Head Face Pain. 2015;55(6):885–916.CrossRefGoogle Scholar
Adler, H, Burnett, CJ. “Psychic poisons” or emerging medicines: a thematic analysis of cannabis representations in Australian nineteenth-century periodicals. J Commun Inquiry. 2024:1–21. https://doi.org/10.1177/01968599241248611.CrossRefGoogle Scholar
Malleck, D., ed. Drugs, Alcohol and Addiction in the Long Nineteenth Century. 2020. Vol. I (1st ed.). London: Routledge. https://doi.org/10.4324/9780429436116.Google Scholar
Allen, M, Thomas, N. Problem substances: temperance and the control of addictive drugs in nineteenth-century Australia. Soc Hist Alcohol Drugs. 2021;35(1):3–32.CrossRefGoogle Scholar
Mathre, M, Byrne, A. Cannabis series – the whole story Part 3: the US Cannabis prohibition and beyond. Drugs Alcohol Today. 2002;2(1):4–9.Google Scholar
Bridgeman, MB, Abazia, DT. Medicinal cannabis: history, pharmacology, and implications for the acute care setting. P&T. 2017;42(3):180–188.Google ScholarPubMed
Aldrich, M. History of therapeutic cannabis. In Mathre, ML, ed. Cannabis in Medical Practice: A Legal, Historical and Pharmacological Overview of the Therapeutic Use of Marijuana. Jefferson, NC: McFarland & Company; 1997:35–55.Google Scholar
Adams, R, Hunt, M, Clark, JH. Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. J Am Chem Soc. 1940;62:196–200.CrossRefGoogle Scholar
Mechoulam, R, Shvo, Y. Hashish. I. The structure of cannabidiol. Tetrahedron. 1963;19(12):2073–2078.CrossRefGoogle Scholar
Gaoni, Y, Mechoulam, R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86:1646–1647.CrossRefGoogle Scholar
Devane, WA, Dysarz, FA 3rd, Johnson, MR, Melvin, LS, Howlett, AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34(5):605–613.CrossRefGoogle ScholarPubMed
Munro, S, Thomas, KL, Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61–65.CrossRefGoogle ScholarPubMed
Maccarrone, M, Bab, I, Biro, T, et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci. 2015;36(5):277–296.CrossRefGoogle ScholarPubMed
Russo, EB. Beyond cannabis: plants and the endocannabinoid system. Trends Pharmacol Sci. 2016;37(7):594–605. doi:10.1016/j.tips.2016.04.005. Epub 2016 May 11. PMID: 27179600.CrossRefGoogle ScholarPubMed
Shahbazi, F, Grandi, V, Banerjee, A, Trant, JF. Cannabinoids and cannabinoid receptors: the story so far. iScience. 2020;23(7):101301.CrossRefGoogle ScholarPubMed
Zou, S, Kumar, U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci. 2018;19(3):833. doi:10.3390/ijms19030833. PMID: 29533978; PMCID: PMC5877694.CrossRefGoogle ScholarPubMed
Mackie, K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol. 2005;168:299–325.CrossRefGoogle Scholar
Mackie, K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol. 2008;20 (Suppl 1):10–14.CrossRefGoogle Scholar
Pertwee, R. Pharmacological and therapeutic targets for Δ9tetrahydrocannabinol and cannabidiol. Euphytica. 2004;140:73–82.CrossRefGoogle Scholar
Lu, HC, Mackie, K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016;79(7):516–525.CrossRefGoogle Scholar
Tao, Y, Li, L, Jiang, B, et al. Cannabinoid receptor-2 stimulation suppresses neuroinflammation by regulating microglial M1/M2 polarization through the cAMP/PKA pathway in an experimental GMH rat model. Brain Behav Immun. 2016;58:118–129. doi: 10.1016/j.bbi.2016.05.020. Epub 2016 May 31. PMID: 27261088.CrossRefGoogle Scholar
Bie, B, Wu, J, Foss, JF, Naguib, M. An overview of the cannabinoid type 2 receptor system and its therapeutic potential. Curr Opin Anaesthesiol. 2018;31(4):407–414.CrossRefGoogle ScholarPubMed
Maresz, K, Carrier, EJ, Ponomarev, ED, Hillard, CJ, Dittel, BN. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem. 2005;95(2):437–445.CrossRefGoogle ScholarPubMed
Howlett, AC. The cannabinoid receptors. Prostaglandins Other Lipid Mediat. 2002;68–69:619–631.CrossRefGoogle ScholarPubMed
Yang, H, Zhou, J, Lehmann, C. GPR55 – a putative “type 3” cannabinoid receptor in inflammation. J Basic Clin Physiol Pharmacol. 2016;27(3):297–302.CrossRefGoogle ScholarPubMed
Brown, AJ. Novel cannabinoid receptors. Br J Pharmacol. 2007;152(5):567–575.CrossRefGoogle ScholarPubMed
Penumarti, A, Abdel-Rahman, AA. The novel endocannabinoid receptor GPR18 is expressed in the rostral ventrolateral medulla and exerts tonic restraining influence on blood pressure. J Pharmacol Exp Ther. 2014;349(1):29–38.CrossRefGoogle ScholarPubMed
Devane, W, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946–1949.CrossRefGoogle Scholar
Mechoulam, R, Ben-Shabat, S, Hanus, L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995;50(1):83–90.CrossRefGoogle ScholarPubMed
Sugiura, T, Kondo, S, Sukagawa, A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 1995;215(1):89–97.CrossRefGoogle ScholarPubMed
Scherma, M, Masia, P, Satta, V, et al. Brain activity of anandamide: a rewarding bliss? Acta Pharmacol Sin. 2019;40(3):309–323.CrossRefGoogle ScholarPubMed
Ohno-Shosaku, T, Kano, M. Endocannabinoid-mediated retrograde modulation of synaptic transmission. Curr Opin Neurobiol. 2014;29:1–8.CrossRefGoogle ScholarPubMed
Ross, RA. Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol. 2003;140(5):790–801.CrossRefGoogle ScholarPubMed
Maccarrone, M, Finazzi-Agro, A. The endocannabinoid system, anandamide and the regulation of mammalian cell apoptosis. Cell Death Differ. 2003;10(9):946–955.CrossRefGoogle ScholarPubMed
Zhang, H, Li, X, Liao, D, Luo, P, Jiang, X. Alpha/beta-hydrolase domain-containing 6:signaling and function in the central nervous system. Front Pharmacol. 2021;12:784202.CrossRefGoogle ScholarPubMed
Bononi, G, Tuccinardi, T, Rizzolio, F, Granchi, C. Alpha/beta-hydrolase domain (ABHD) inhibitors as new potential therapeutic options against lipid-related diseases. J Med Chem. 2021;64(14):9759–9785.CrossRefGoogle Scholar
Rodríguez de Fonseca, F, Del Arco, I, Bermudez-Silva, FJ, et al. The endocannabinoid system:physiology and pharmacology. Alcohol Alcohol. 2005;40(1):2–14.CrossRefGoogle ScholarPubMed
Pacher, P, Batkai, S, Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3):389–462.CrossRefGoogle Scholar
Mechoulam, R, Parker, LA. The endocannabinoid system and the brain. Annu Rev Psychol. 2013;64:21–47.CrossRefGoogle ScholarPubMed
Battista, N, Di Tommaso, M, Bari, M, Maccarrone, M. The endocannabinoid system: an overview. Front Behav Neurosci. 2012;6:9.CrossRefGoogle ScholarPubMed
ElSohly, M. Chemical constituents of cannabis. In Grotenherman, F, Russo, E, eds. Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential. New York: Haworth Press; 2002.Google Scholar
Pate, D. Chemical ecology of Cannabis. J Int Hemp Assoc. 1994;2:32–37.Google Scholar
Franco, G, Smid, S, Viegas, C Jr. Phytocannabinoids: general aspects and pharmacological potential in neurodegenerative diseases. Curr Neuropharmacol. 2021;19(4):449–464.CrossRefGoogle Scholar
Berman, P, Futoran, K, Lewitus, GM, et al. A new ESI-LC/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis. Sci Rep. 2018;8(1):14280.CrossRefGoogle ScholarPubMed
Giacoppo, S, Mandolino, G, Galuppo, M, Bramanti, P, Mazzon, E. Cannabinoids: new promising agents in the treatment of neurological diseases. Molecules. 2014;19(11):18781–18816.CrossRefGoogle ScholarPubMed
Hanus, LO, Meyer, SM, Munoz, E, Taglialatela-Scafati, O, Appendino, G. Phytocannabinoids: a unified critical inventory. Nat Prod Rep. 2016;33(12):1357–1392.CrossRefGoogle ScholarPubMed
Alcohol, Drugs and Addictive Behaviours. Cannabis. World Health Organization. 2024. www.who.int/teams/mental-health-and-substance-use/alcohol-drugs-and-addictive-behaviours/drugs-psychoactive/cannabis.Google Scholar
Pertwee, RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199–215.CrossRefGoogle ScholarPubMed
Howlett, AC, Blume, LC, Dalton, GD. CB(1) cannabinoid receptors and their associated proteins. Curr Med Chem. 2010;17(14):1382–1393.CrossRefGoogle ScholarPubMed
Morales, P, Hurst, DP, Reggio, PH. Molecular targets of the phytocannabinoids: a complex picture. Prog Chem Org Nat Prod. 2017;103:103–131.Google ScholarPubMed
Sulcova, A. Pharmacodynamics of cannabinoids. Arch Pharm Pharma Sci. 2019;3:11–18.CrossRefGoogle Scholar
Ramirez-Orozco, RE, Garcia-Ruiz, R, Morales, P, et al. Potential metabolic and behavioural roles of the putative endocannabinoid receptors GPR18, GPR55 and GPR119 in feeding. Curr Neuropharmacol. 2019;17(10):947–960.CrossRefGoogle Scholar
Rahn, EJ, Hohmann, AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics. 2009;6(4):713–737.CrossRefGoogle ScholarPubMed
Aggarwal, SK. Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial results. Clin J Pain. 2013;29(2):162–171.CrossRefGoogle ScholarPubMed
Kopustinskiene, DM, Masteikova, R, Lazauskas, R, Bernatoniene, J., Cannabis Sativa, L. Bioactive compounds and their protective role in oxidative stress and inflammation. Antioxidants (Basel). 2022;11(4):660. doi:10.3390/antiox11040660. PMID: 35453344; PMCID: PMC9030479.CrossRefGoogle ScholarPubMed
Kaul, M, Zee, PC, Sahni, AS. Effects of cannabinoids on sleep and their therapeutic potential for sleep disorders. Neurotherapeutics. 2021;18(1):217–227.CrossRefGoogle ScholarPubMed
Hampson, AJ, Grimaldi, M, Axelrod, J, Wink, D. Cannabidiol and (-) delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA. 1998;95(14):8268–8273.CrossRefGoogle ScholarPubMed
Williams, SJ, Hartley, JP, Graham, JD. Bronchodilator effect of delta1tetrahydrocannabinol administered by aerosol of asthmatic patients. Thorax. 1976;31(6):720–723.CrossRefGoogle ScholarPubMed
Munson, AE, Harris, LS, Friedman, MA, Dewey, WL, Carchman, RA. Antineoplastic activity of cannabinoids. J Natl Cancer Inst. 1975;55(3):597–602.CrossRefGoogle ScholarPubMed
Sanchez, C, Galve-Roperh, I, Canova, C, Brachet, P, Guzman, M. Delta9tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett. 1998;436(1):6–10.CrossRefGoogle ScholarPubMed
Blazquez, C, Salazar, M, Carracedo, A, et al. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer Res. 2008;68(6):1945–1952.CrossRefGoogle ScholarPubMed
Carracedo, A, Gironella, M, Lorente, M, et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res. 2006;66(13):6748–6755.CrossRefGoogle ScholarPubMed
Ruiz, L, Miguel, A, Diaz-Laviada, I. Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Lett. 1999;458(3):400–404.CrossRefGoogle Scholar
Leelawat, S, Leelawat, K, Narong, S, Matangkasombut, O. The dual effects of delta(9)-tetrahydrocannabinol on cholangiocarcinoma cells: anti-invasion activity at low concentration and apoptosis induction at high concentration. Cancer Invest. 2010;28(4):357–363.CrossRefGoogle Scholar
Whyte, DA, Al-Hammadi, S, Balhaj, G, et al. Cannabinoids inhibit cellular respiration of human oral cancer cells. Pharmacology. 2010;85(6):328–335.CrossRefGoogle ScholarPubMed
Machado Rocha, FC, Stefano, SC, De Cassia Haiek, R, Rosa Oliveira, LM, Da Silveira, DX. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl). 2008;17(5):431–443.Google ScholarPubMed
Berman, JS, Symonds, C, Birch, R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain. 2004;112(3):299–306.CrossRefGoogle ScholarPubMed
Eisenberg, E, Ogintz, M, Almog, S. The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a Phase 1a study. J Pain Palliat Care Pharmacother. 2014;28(3):216–225.CrossRefGoogle ScholarPubMed
McGeeney, BE. Cannabinoids and hallucinogens for headache. Headache. 2013;53(3):447–458.CrossRefGoogle ScholarPubMed
Noyes, R Jr., Brunk, SF, Baram, DA, Canter, A. Analgesic effect of delta-9tetrahydrocannabinol. J Clin Pharmacol. 1975;15(2–3):139–143.CrossRefGoogle Scholar
McCabe, M, Smith, FP, Macdonald, JS, et al. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Invest New Drugs. 1988;6(3):243–246.CrossRefGoogle ScholarPubMed
Notcutt, W, Price, M, Miller, R, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 “N of 1” studies. Anaesthesia. 2004;59(5):440–452.CrossRefGoogle ScholarPubMed
National Academies of Sciences, Engineering and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press; 2017.Google Scholar
Wade, DT, Makela, P, Robson, P, House, H, Bateman, C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10(4):434–441.CrossRefGoogle ScholarPubMed
Currais, A, Quehenberger, O., M Armando, A. et al. Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids. NPJ Aging Mech Dis. 2016;2:16012. https://doi.org/10.1038/npjamd.2016.12CrossRefGoogle ScholarPubMed
Merritt, JC, Crawford, WJ, Alexander, PC, Anduze, AL, Gelbart, SS. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology. 1980;87(3):222–228.CrossRefGoogle ScholarPubMed
Jarvinen, T, Pate, DW, Laine, K. Cannabinoids in the treatment of glaucoma. Pharmacol Ther. 2002;95(2):203–220.CrossRefGoogle ScholarPubMed
Lucas, CJ, Galettis, P, Schneider, J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018;84(11): 2477–2482.CrossRefGoogle ScholarPubMed
Grotenhermen, F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42:327–360.CrossRefGoogle ScholarPubMed
Chayasirisobhon, S. Mechanisms of action and pharmacokinetics of cannabis. Perm J. 2020;25:1–3.Google ScholarPubMed
Huestis, MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770–1804.CrossRefGoogle ScholarPubMed
MacCallum, CA, Russo, EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12–19.CrossRefGoogle ScholarPubMed
Gieringer, D, St. Laurent, S., Goodrich, S. Cannabis vaporizer combines efficient delivery of THC with effective suppression of pyrolytic compounds. J Cannabis Ther. 2004;1:7–27.CrossRefGoogle Scholar
Newmeyer, MN, Swortwood, MJ, Barnes, AJ, et al. Free and glucuronide whole blood cannabinoids’ pharmacokinetics after controlled smoked, vaporized, and oral cannabis administration in frequent and occasional cannabis users: identification of recent cannabis intake. Clin Chem. 2016;62(12):1579–1592.CrossRefGoogle ScholarPubMed
Lunn, S, Diaz, P, O’Hearn, S, et al. Human pharmacokinetic parameters of orally administered delta(9)-tetrahydrocannabinol capsules are altered by fed versus fasted conditions and sex differences. Cannabis Cannabinoid Res. 2019;4(4):255–264.CrossRefGoogle ScholarPubMed
Perkins, D, Brophy, H, McGregor, IS, et al. Medicinal cannabis and driving: the intersection of health and road safety policy. Int J Drug Policy. 2021;97:103307.CrossRefGoogle ScholarPubMed
Lemberger, L, Crabtree, RE, Rowe, HM. 11-hydroxy-9-tetrahydrocannabinol: pharmacology, disposition, and metabolism of a major metabolite of marihuana in man. Science. 1972;177(4043):62–64.CrossRefGoogle Scholar
Cannabidiol (CBD): Critical Review Report. Expert Committee on Drug Dependence. Fortieth Meeting, Geneva, 4–7 June 2018. https://cdn.who.int/media/docs/default-source/controlled-substances/whocbdreportmay2018-2.pdf?omnisendContactID=6324d469573db4001c1c0414&sfvrsn=f78db77_2. Accessed September 3, 2024.Google Scholar
Britch, SC, Babalonis, S, Walsh, SL. Cannabidiol: pharmacology and therapeutic targets. Psychopharmacology (Berl). 2021;238(1):9–28.CrossRefGoogle ScholarPubMed
Laprairie, RB, Bagher, AM, Kelly, ME, Denovan-Wright, EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172(20):4790–4805.CrossRefGoogle ScholarPubMed
Russo, EB, Burnett, A, Hall, B, Parker, KK. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005;30(8):1037–1043.CrossRefGoogle ScholarPubMed
Bisogno, T, Hanus, L, De Petrocellis, L, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 2001;134(4):845–852.CrossRefGoogle ScholarPubMed
Castillo-Arellano, J, Canseco-Alba, A, Cutler, SJ, Leon, F. The polypharmacological effects of cannabidiol. Molecules. 2023;28(7):3271. doi: 10.3390/molecules28073271. PMID: 37050032; PMCID: PMC10096752.CrossRefGoogle ScholarPubMed
Kathmann, M, Flau, K, Redmer, A, Trankle, C, Schlicker, E. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedebergs Arch Pharmacol. 2006;372(5):354–361.CrossRefGoogle Scholar
Mlost, J, Bryk, M, Starowicz, K. Cannabidiol for pain treatment: focus on pharmacology and mechanism of action. Int J Mol Sci. 2020;21(22):8870. doi:10.3390/ijms21228870. PMID: 33238607; PMCID: PMC7700528.CrossRefGoogle ScholarPubMed
Taylor, L, Gidal, B, Blakey, G, Tayo, B, Morrison, G. A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs. 2018;32(11):1053–1067.CrossRefGoogle ScholarPubMed
Martinez Naya, N, Kelly, J, Corna, G, et al. Molecular and cellular mechanisms of action of cannabidiol. Molecules. 2023;28(16):5980. doi:10.3390/molecules28165980. PMID: 37630232; PMCID: PMC10458707.CrossRefGoogle ScholarPubMed
Millar, SA, Stone, NL, Yates, AS, O’Sullivan, SE. A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol. 2018;9:1365.CrossRefGoogle ScholarPubMed
Australian Government. Safety of Low Dose Cannabidiol. Canberra, ACT: Therapeutic Goods Administration. Australian Government; 2020:1–20.Google Scholar
Zendulka, O, Dovrtelova, G, Noskova, K, et al. Cannabinoids and cytochrome P450 interactions. Curr Drug Metab. 2016;17(3):206–226.CrossRefGoogle ScholarPubMed
Burstein, S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg Med Chem. 2015;23(7):1377–1385.CrossRefGoogle ScholarPubMed
Sanchez, AJ, Garcia-Merino, A. Neuroprotective agents: cannabinoids. Clin Immunol. 2012;142(1):57–67.CrossRefGoogle ScholarPubMed
Castillo, A, Tolon, MR, Fernandez-Ruiz, J, Romero, J, Martinez-Orgado, J. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors. Neurobiol Dis. 2010;37(2):434–440.CrossRefGoogle Scholar
Bergamaschi, MM, Queiroz, RH, Chagas, MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology. 2011;36(6):1219–1226.CrossRefGoogle ScholarPubMed
Zanelati, TV, Biojone, C, Moreira, FA, Guimaraes, FS, Joca, SR. Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol. 2010;159(1):122–128.CrossRefGoogle ScholarPubMed
Solinas, M, Massi, P, Cantelmo, AR, et al. Cannabidiol inhibits angiogenesis by multiple mechanisms. Br J Pharmacol. 2012;167(6):1218–1231.CrossRefGoogle ScholarPubMed
Brown, JD, Winterstein, AG. Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. J Clin Med. 2019;8(7):989. doi:10.3390/jcm8070989. PMID: 31288397; PMCID: PMC6678684.CrossRefGoogle ScholarPubMed
Walsh, KB, McKinney, AE, Holmes, AE. Minor cannabinoids: biosynthesis, molecular pharmacology and potential therapeutic uses. Front Pharmacol. 2021;12:777804.CrossRefGoogle ScholarPubMed
Cuttler, C, Stueber, A, Cooper, ZD, Russo, E. Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial. Sci Rep. 2024;14(1):16163.CrossRefGoogle Scholar
Calapai, F, Cardia, L, Esposito, E, et al. Pharmacological aspects and biological effects of cannabigerol and its synthetic derivatives. Evid Based Complement Alternat Med. 2022;2022:3336516.CrossRefGoogle ScholarPubMed
Jastrzab, A, Jarocka-Karpowicz, I, Skrzydlewska, E. The origin and biomedical relevance of cannabigerol. Int J Mol Sci. 2022;23(14):7929. doi:10.3390/ijms23147929. PMID: 35887277; PMCID: PMC9322760.CrossRefGoogle ScholarPubMed
Adams, R, Baker, BR, Wearn, RB. Structure of cannabinol. III. Synthesis of cannabinol, 1-hydroxy-3-n-amyl-6,6,9-trimethyl-6-dibenzopyran. JACS. 1940;62(8):2204–2207. https://doi.org/10.1021/ja01865a083.CrossRefGoogle Scholar
Khouchlaa, A, Khouri, S, Hajib, A, et al. Health benefits, pharmacological properties, and metabolism of cannabinol: a comprehensive review. Ind. Crops Prod. 2024;213:118359.CrossRefGoogle Scholar
Maioli, C, Mattoteia, D, Amin, HIM, Minassi, A, Caprioglio, D. Cannabinol: history, syntheses, and biological profile of the greatest “Minor” cannabinoid. Plants (Basel). 2022;11(21):2896. doi: 10.3390/plants11212896. PMID: 36365350; PMCID: PMC9658060.Google ScholarPubMed
Tahir, MN, Shahbazi, F, Rondeau-Gagne, S, Trant, JF. The biosynthesis of the cannabinoids. J Cannabis Res. 2021;3(1):7.CrossRefGoogle ScholarPubMed
Izzo, AA, Capasso, R, Aviello, G, et al. Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. Br J Pharmacol. 2012;166(4):1444–1460.CrossRefGoogle Scholar
Udoh, M, Santiago, M, Devenish, S, McGregor, IS, Connor, M. Cannabichromene is a cannabinoid CB(2) receptor agonist. Br J Pharmacol. 2019;176(23):4537–4547.CrossRefGoogle ScholarPubMed
Gaoni, Y, Mechoulam, R. Cannabichromene, a new active principle in hashish. Chem Commun. 1966;1:20–21.Google Scholar
Zagzoog, A, Mohamed, KA, Kim, HJJ, et al. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. Sci Rep. 2020;10(1):20405.CrossRefGoogle ScholarPubMed
Abdel-Kader, MS, Radwan, MM, Metwaly, AM, et al. Chemistry and pharmacology of delta-8-tetrahydrocannabinol. Molecules. 2024;29(6).CrossRefGoogle ScholarPubMed
Bozman, ME, Manoharan, SVRR, Vasavada, T. Marijuana variant of concern: delta 8-tetrahydrocannabinol (delta-8-THC, Δ8-THC). Psychiatry Res Case Rep. 2022;1(2):100028.Google Scholar
Kruger, JS, Kruger, DJ. Delta-8-THC: delta-9-THC’s nicer younger sibling? J Cannabis Res. 2022;4(1):4.CrossRefGoogle ScholarPubMed
Tagen, M, Klumpers, LE. Review of delta-8-tetrahydrocannabinol (Delta (8) – THC): comparative pharmacology with Delta(9) – THC. Br J Pharmacol. 2022;179(15):3915–3933.CrossRefGoogle Scholar
Hollister, LE, Gillespie, HK. Delta-8- and delta-9-tetrahydrocannabinol comparison in man by oral and intravenous administration. Clin Pharmacol Ther. 1973;14(3):353–357.CrossRefGoogle Scholar
Leas, EC, Harati, RM, Satybaldiyeva, N, et al. Self-reported adverse events associated with Δ(8)-tetrahydrocannabinol (delta-8-THC) use. J Cannabis Res. 2023;5(1):15.CrossRefGoogle Scholar
LoParco, CR, Rossheim, ME, Walters, ST, et al. Delta-8 tetrahydrocannabinol: a scoping review and commentary. Addiction. 2023;118(6):1011–1028.CrossRefGoogle Scholar
Dwivedi, C, Harbison, RD. Anticonvulsant activities of delta-8 and delta-9 tetrahydrocannabinol and uridine. Toxicol Appl Pharmacol. 1975;31(3):452–458.CrossRefGoogle ScholarPubMed
Semlali, A, Beji, S, Ajala, I, Rouabhia, M. Effects of tetrahydrocannabinols on human oral cancer cell proliferation, apoptosis, autophagy, oxidative stress, and DNA damage. Arch Oral Biol. 2021;129:105200.CrossRefGoogle ScholarPubMed
Langenheim, JH. Higher plant terpenoids: a phytocentric overview of their ecological roles. J Chem Ecol. 1994;20(6):1223–1280.CrossRefGoogle ScholarPubMed
Siddiqui, T, Khan, MU, Sharma, V, Gupta, K. Terpenoids in essential oils: chemistry, classification, and potential impact on human health and industry. Phytomedicine Plus. 2024;4(2):100549.CrossRefGoogle Scholar
Lydon, J, Teramura, AH, Coffman, CB. UV-B radiation effects on photosynthesis, growth and cannabinoid production of two Cannabis sativa chemotypes. Photochem Photobiol. 1987;46(2):201–206.CrossRefGoogle ScholarPubMed
Masyita, A, Mustika Sari, R, Dwi Astuti, A, et al. Terpenes and terpenoids as main bioactive compounds of essential oils, their roles in human health and potential application as natural food preservatives. Food Chem X. 2022;13:100217.CrossRefGoogle Scholar
Chacon, FT, Raup-Konsavage, WM, Vrana, KE, Kellogg, JJ. Secondary terpenes in Cannabis sativa L.: synthesis and synergy. Biomedicines. 2022;10(12).CrossRefGoogle ScholarPubMed
Surendran, S, Qassadi, F, Surendran, G, Lilley, D, Heinrich, M. Myrcene – what are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666.CrossRefGoogle ScholarPubMed
do Vale, TG, Furtado, EC, Santos, JG Jr., Viana, GS. Central effects of citral, myrcene and limonene, constituents of essential oil chemotypes from Lippia alba (Mill.) n.e. Brown. Phytomedicine. 2002;9(8):709–714.CrossRefGoogle ScholarPubMed
Rufino, AT, Ribeiro, M, Sousa, C, et al. Evaluation of the anti-inflammatory, anti-catabolic and pro-anabolic effects of E-caryophyllene, myrcene and limonene in a cell model of osteoarthritis. Eur J Pharmacol. 2015;750:141–150.CrossRefGoogle Scholar
Miyazawa, M, Yamafuji, C. Inhibition of acetylcholinesterase activity by bicyclic monoterpenoids. J Agric Food Chem. 2005;53(5):1765–1768.CrossRefGoogle ScholarPubMed
Sommano, SR, Chittasupho, C, Ruksiriwanich, W, Jantrawut, P. The cannabis terpenes. Molecules. 2020;25(24).CrossRefGoogle ScholarPubMed
Salehi, B, Upadhyay, S, Erdogan Orhan, I, et al. Therapeutic potential of alpha- and beta-pinene: a miracle gift of nature. Biomolecules. 2019;9(11):738. doi:10.3390/biom9110738. PMID: 31739596; PMCID: PMC6920849.CrossRefGoogle ScholarPubMed
Lin, H, Li, Z, Sun, Y, et al. D-limonene: promising and sustainable natural bioactive compound. Appl Sci. 2024;14(11):4605.CrossRefGoogle Scholar
Eddin, LB, Jha, NK, Meeran, MFN, et al. Neuroprotective potential of limonene and limonene containing natural products. Molecules. 2021;26(15):4535. doi:10.3390/molecules26154535. PMID: 34361686; PMCID: PMC8348102.CrossRefGoogle ScholarPubMed
Hashiesh, HM, Sharma, C, Goyal, SN, et al. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639.CrossRefGoogle ScholarPubMed
Hanus, LO, Hod, Y. Terpenes/terpenoids in cannabis: are they important? Med Cannabis Cannabinoids. 2020;3(1):25–60.CrossRefGoogle ScholarPubMed
Dalavaye, N, Nicholas, M, Pillai, M, Erridge, S, Sodergren, MH. The clinical translation of alpha-humulene – a scoping review. Planta Med. 2024;90 (9):664–674.Google ScholarPubMed
Desaulniers Brousseau, V, Wu, BS, MacPherson, S, Morello, V, Lefsrud, M. Cannabinoids and terpenes: how production of photo-protectants can be manipulated to enhance Cannabis sativa L. phytochemistry. Front Plant Sci. 2021;12:620021.CrossRefGoogle ScholarPubMed
Lopez, V, Nielsen, B, Solas, M, Ramirez, MJ, Jager, AK. Exploring pharmacological mechanisms of lavender (Lavandula angustifolia) essential oil on central nervous system targets. Front Pharmacol. 2017;8:280.CrossRefGoogle ScholarPubMed
Dos Santos, ERQ, Maia, JGS, Fontes-Junior, EA, do Socorro Ferraz Maia, C. Linalool as a therapeutic and medicinal tool in depression treatment: a review. Curr Neuropharmacol. 2022;20(6):1073–1092.CrossRefGoogle ScholarPubMed
Maczka, W, Duda-Madej, A, Grabarczyk, M, Winska, K. Natural compounds in the battle against microorganisms – linalool. Molecules. 2022;27(20):6928. doi:10.3390/molecules27206928. PMID: 36296521; PMCID: PMC9609897.CrossRefGoogle ScholarPubMed
Nagoor Meeran, MF, Javed, H, Al Taee, H, Azimullah, S, Ojha, SK. Pharmacological properties and molecular mechanisms of thymol: prospects for its therapeutic potential and pharmaceutical development. Front Pharmacol. 2017;8:380.CrossRefGoogle ScholarPubMed
Bone, K. A Clinical Guide to Blending Liquid Herbs: Herbal Formulations for the Individual Patient. St. Louis, MO: Churchill Livingstone; 2003.Google Scholar
Ben-Shabat, S, Fride, E, Sheskin, T, et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol. 1998;353(1):23–31.CrossRefGoogle ScholarPubMed
Christensen, C, Rose, M, Cornett, C, Alleso, M. Decoding the postulated entourage effect of medicinal cannabis: what it is and what it isn’t. Biomedicines. 2023;11(8):2323. doi:10.3390/biomedicines11082323. PMID: 37626819; PMCID: PMC10452568.CrossRefGoogle ScholarPubMed
Sinclair, J, Toufaili, Y, Gock, S, et al. Cannabis use for endometriosis: clinical and legal challenges in Australia and New Zealand. Cannabis Cannabinoid Res. 2022;7(4):464–472.CrossRefGoogle ScholarPubMed
Cherkasova, V, Wang, B, Gerasymchuk, M, et al. Use of cannabis and cannabinoids for treatment of cancer. Cancers. 2022;14(20):5142.CrossRefGoogle ScholarPubMed
Velasco, G, Sánchez, C, Guzmán, M. Towards the use of cannabinoids as antitumour agents. Nature Reviews Cancer. 2012;12(6):436–444.CrossRefGoogle ScholarPubMed
Messalli, EM, Grauso, F, Luise, R, Angelini, A, Rossiello, R. Cannabinoid receptor type 1 immunoreactivity and disease severity in human epithelial ovarian tumors. Am J Obstetr Gynecol. 2014;211(3):234.e1-e6.CrossRefGoogle ScholarPubMed
Michalski, CW, Oti, FE, Erkan, M, et al. Cannabinoids in pancreatic cancer: correlation with survival and pain. Int J Cancer. 2008;122(4):742–750.CrossRefGoogle ScholarPubMed
Chung, SC, Hammarsten, P, Josefsson, A, et al. A high cannabinoid CB1 receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur J Cancer. 2009;45(1):174–182.CrossRefGoogle ScholarPubMed
Jung, CK, Kang, WK, Park, JM, et al. Expression of the cannabinoid type I receptor and prognosis following surgery in colorectal cancer. Oncol Lett. 2013;5(3):870–876.CrossRefGoogle ScholarPubMed
Pérez-Gómez, E, Andradas, C, Blasco-Benito, S, et al. Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer. J Natl Cancer Inst. 2015;107(6):djv077.CrossRefGoogle ScholarPubMed
Klein Nulent, TJW, Van Diest, PJ, van der Groep, P, et al. Cannabinoid receptor-2 immunoreactivity is associated with survival in squamous cell carcinoma of the head and neck. Br J Oral Maxillofacial Surg. 2013;51(7):604–609.CrossRefGoogle ScholarPubMed
Milian, L, Mata, M, Alcacer, J, et al. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro. PLoS One. 2020;15(2):e0228909.CrossRefGoogle ScholarPubMed
Ligresti, A, Bisogno, T, Matias, I, et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology. 2003;125(3):677–687.CrossRefGoogle ScholarPubMed
Takeda, S, Yoshida, K, Nishimura, H, et al. Δ9-tetrahydrocannabinol disrupts estrogen-signaling through up-regulation of estrogen receptor β (ERβ). Chem Res Toxicol. 2013;26(7):1073–1079.CrossRefGoogle ScholarPubMed
Von Bueren, A, Schlumpf, M, Lichtensteiger, W. Delta (9)-tetrahydrocannabinol inhibits 17β-estradiol-induced proliferation and fails to activate androgen and estrogen receptors in MCF7 human breast cancer cells. Anticancer Res. 2008;28(1A):85–89.Google ScholarPubMed
Caffarel, MM, Sarrió, D, Palacios, J, Guzmán, M, Sánchez, C. Δ9tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res. 2006;66(13):6615–6621.CrossRefGoogle Scholar
McKallip, RJ, Nagarkatti, M, Nagarkatti, PS. Δ-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J Immunol. 2005;174(6):3281–3289.CrossRefGoogle ScholarPubMed
Semlali, A, Beji, S, Ajala, I, Rouabhia, M. Effects of tetrahydrocannabinols on human oral cancer cell proliferation, apoptosis, autophagy, oxidative stress, and DNA damage. Arch Oral Biol. 2021;129:105200.CrossRefGoogle ScholarPubMed
Seltzer, ES, Watters, AK, MacKenzie, D Jr., Granat, LM, Zhang, D. Cannabidiol (CBD) as a promising anti-cancer drug. Cancers (Basel). 2020;12(11):3203. doi:10.3390/cancers12113203. PMID: 33143283; PMCID: PMC7693730.CrossRefGoogle ScholarPubMed
O’Brien, K. Cannabidiol (CBD) in cancer management. Cancers (Basel). 2022;14(4).CrossRefGoogle ScholarPubMed
McAllister, SD, Soroceanu, L, Desprez, P-Y. The antitumor activity of plant-derived non-psychoactive cannabinoids. J Neuroimmune Pharmacol. 2015;10(2):255–267.CrossRefGoogle ScholarPubMed
Nakamura, H, Takada, K. Reactive oxygen species in cancer: current findings and future directions. Cancer Sci. 2021;112(10):3945–3952.CrossRefGoogle ScholarPubMed
Massi, P, Vaccani, A, Bianchessi, S, et al. The nonpsychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol Life Sci. 2006;63(17):2057–2066.CrossRefGoogle ScholarPubMed
Tramèr, MR, Carroll, D, Campbell, FA, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001;323(7303):16.CrossRefGoogle ScholarPubMed
Whiting, PF, Wolff, RF, Deshpande, S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456–2473.CrossRefGoogle ScholarPubMed
Chow, R, Valdez, C, Chow, N, et al. Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting – a systematic review and meta-analysis. Support Care Cancer. 2020;28:2095–2103.Google ScholarPubMed
Abrams, DI. Cannabis, cannabinoids and cannabis-based medicines in cancer care. Integr Cancer Therap. 2022;21:15347354221081772.CrossRefGoogle ScholarPubMed
Hesketh, PJ, Kris, MG, Basch, E, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782–2797.CrossRefGoogle ScholarPubMed
Foltin, RW, Fischman, MW, Byrne, MF. Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite. 1988;11(1):1–14.CrossRefGoogle Scholar
Turcott, JG, del Rocío Guillen Núñez, M, Flores-Estrada, D, et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer. 2018;26:3029–3038.Google ScholarPubMed
Rahn, E, Makriyannis, A, Hohmann, A. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol. 2007;152(5):765–777.CrossRefGoogle ScholarPubMed
Lynch, ME, Cesar-Rittenberg, P, Hohmann, AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Sympt Manag. 2014;47(1):166–173.CrossRefGoogle ScholarPubMed
Boland, EG, Bennett, MI, Allgar, V, Boland, JW. Cannabinoids for adult cancer-related pain: systematic review and meta-analysis. BMJ Support Palliat Care. 2020;10(1):14–24.CrossRefGoogle ScholarPubMed
Twelves, C, Sabel, M, Checketts, D, et al. A Phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma. Br J Cancer. 2021;124(8):1379–1387.CrossRefGoogle ScholarPubMed
Schloss, J, Lacey, J, Sinclair, J, et al. A Phase 2 randomised clinical trial assessing the tolerability of two different ratios of medicinal cannabis in patients with high grade gliomas. Front Oncol. 2021;11:649555. doi:10.3389/fonc.2021.649555. PMID: 34094937; PMCID: PMC8176855.CrossRefGoogle ScholarPubMed
Warren, PP, Bebin, EM, Nabors, LB, Szaflarski, JP. The use of cannabidiol for seizure management in patients with brain tumor-related epilepsy. Neurocase. 2017;23(5–6):287–291.CrossRefGoogle ScholarPubMed
Szaflarski, JP, Hernando, K, Bebin, EM, et al. Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol. Epilepsy Behav. 2019;95:131–136.CrossRefGoogle ScholarPubMed
Fragoso, YD, Carra, A, Macias, MA. Cannabis and multiple sclerosis. Expert Rev Neurotherap. 2020;20(8):849–854.CrossRefGoogle ScholarPubMed
Haddad, F, Dokmak, G, Karaman, R. The efficacy of cannabis on multiple sclerosis-related symptoms. Life. 2022;12(5):682.CrossRefGoogle ScholarPubMed
Lacroix, C, Alleman-Brimault, I, Zalta, A, et al. What do we know about medical cannabis in neurological disorders and what are the next steps? Front Pharmacol. 2022;13:883987. doi:10.3389/fphar.2022.883987. PMID: 35571129; PMCID: PMC9091192.CrossRefGoogle ScholarPubMed
Elliott, J, DeJean, D, Clifford, T, et al. Cannabis-based products for pediatric epilepsy: an updated systematic review. Seizure. 2020;75:18–22.CrossRefGoogle ScholarPubMed
Bougea, A, Koros, C, Simitsi, A-M, et al. Medical cannabis as an alternative therapeutics for Parkinson’s disease: systematic review. Complem Therap Clin Pract. 2020;39:101154.CrossRefGoogle Scholar
Stampanoni Bassi, M, Sancesario, A, Morace, R, Centonze, D, Iezzi, E. Cannabinoids in Parkinson’s disease. Cannabis Cannabinoid Res. 2017;2(1):21–29.CrossRefGoogle ScholarPubMed
Venderová, K, Růzicka, E, Vorísek, V, Visnovský, P. Survey on cannabis use in Parkinson’s disease: subjective improvement of motor symptoms. Mov Disord. 2004;19(9):1102–1106.CrossRefGoogle ScholarPubMed
Lotan, I, Treves, TA, Roditi, Y, Djaldetti, R. Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. Clin Neuropharmacol. 2014;37(2):41–44.CrossRefGoogle ScholarPubMed
Urbi, B, Corbett, J, Hughes, I, et al. Effects of cannabis in Parkinson’s disease: a systematic review and meta-analysis. J Parkinson’s Dis. 2021;12(2):495–508.CrossRefGoogle Scholar
Carroll, CB, Bain, PG, Teare, L, et al. Cannabis for dyskinesia in Parkinson disease. Neurology. 2004;63(7):1245–1250CrossRefGoogle ScholarPubMed
van der Stelt, M, Veldhuis, WB, Maccarrone, M, et al. Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol. 2002;26(2–3):317–346.CrossRefGoogle ScholarPubMed
Fernández-Ruiz, J. The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol. 2009;156(7):1029–1040.CrossRefGoogle ScholarPubMed
Sagredo, O, Pazos, MR, Satta, V, et al. Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington’s disease. J Neurosci Res. 2011;89(9):1509–1518.CrossRefGoogle ScholarPubMed
Akinyemi, E, Randhawa, G, Longoria, V, Zeine, R. Medical marijuana effects in movement disorders, focus on Huntington disease: a literature review. J Pharm Pharmaceut Sci. 2020;23:389–395.Google ScholarPubMed
Curtis, A, Mitchell, I, Patel, S, Ives, N, Rickards, H. A pilot study using nabilone for symptomatic treatment in Huntington’s disease. Mov Disord. 2009;24(15):2254–2259.CrossRefGoogle ScholarPubMed
López-Sendón Moreno, JL, García Caldentey, J, Trigo Cubillo, P, et al. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease. J Neurol. 2016;263(7):1390–1400.CrossRefGoogle ScholarPubMed
Consroe, P, Laguna, J, Allender, J, et al. Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol Biochem Behav. 1991;40(3):701–708.CrossRefGoogle ScholarPubMed
Di Marzo, V, Hill, MP, Bisogno, T, Crossman, AR, Brotchie, JM. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson’s disease. FASEB J. 2000;14(10):1432–1438.CrossRefGoogle Scholar
Yoon, DY, Gause, CD, Leckman, JF, Singer, HS. Frontal dopaminergic abnormality in Tourette syndrome: a postmortem analysis. J Neurol Sci. 2007;255(1–2):50–56.CrossRefGoogle ScholarPubMed
Singer, HS, Szymanski, S, Giuliano, J, et al. Elevated intrasynaptic dopamine release in Tourette’s syndrome measured by PET. Am J Psychiatry. 2002;159(8):1329–1336.CrossRefGoogle ScholarPubMed
Giuffrida, A, Parsons, LH, Kerr, TM, et al. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci. 1999;2(4):358–363.CrossRefGoogle ScholarPubMed
Hasan, A, Rothenberger, A, Münchau, A, et al. Oral delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: a case report. J Clin Psychopharmacol. 2010;30(2):190–192.CrossRefGoogle Scholar
Thaler, A, Arad, S, Schleider, LB, et al. Single center experience with medical cannabis in Gilles de la Tourette syndrome. Parkinsonism Relat Disord. 2019;61:211–213.CrossRefGoogle ScholarPubMed
Abi-Jaoude, E, Chen, L, Cheung, P, Bhikram, T, Sandor, P. Preliminary evidence on cannabis effectiveness and tolerability for adults with Tourette syndrome. J Neuropsychiatry Clin Neurosci. 2017;29(4):391–400.CrossRefGoogle ScholarPubMed
Serag, I, Elsakka, MM, MHEd, Moawad, et al. Efficacy of cannabis-based medicine in the treatment of Tourette syndrome: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2024;80(10):1483–1493.CrossRefGoogle ScholarPubMed
Abi-Jaoude, E, Bhikram, T, Parveen, F, et al. A double-blind, randomized, controlled crossover trial of cannabis in adults with Tourette syndrome. Cannabis Cannabinoid Res. 2022;8(5):835–845.CrossRefGoogle ScholarPubMed
Nielsen, S, Germanos, R, Weier, M, et al. The use of cannabis and cannabinoids in treating symptoms of multiple sclerosis: a systematic review of reviews. Curr Neurol Neurosci Rep. 2018;18(2):8.CrossRefGoogle ScholarPubMed
Khan, AA, Shekh-Ahmad, T, Khalil, A, Walker, MC, Ali, AB. Cannabidiol exerts antiepileptic effects by restoring hippocampal interneuron functions in a temporal lobe epilepsy model. Br J Pharmacol. 2018;175(11):2097–2115.CrossRefGoogle Scholar
Rosenberg, EC, Chamberland, S, Bazelot, M, et al. Cannabidiol modulates excitatory-inhibitory ratio to counter hippocampal hyperactivity. Neuron. 2023;111(8):1282–1300.e8.CrossRefGoogle ScholarPubMed
Gray, RA, Whalley, BJ. The proposed mechanisms of action of CBD in epilepsy. Epileptic Disorders. 2020;22(S1):S10–S15.CrossRefGoogle ScholarPubMed
Lazarini-Lopes, W, da Silva-Júnior, RMP, Servilha-Menezes, G, Do Val-da Silva, RA, Garcia-Cairasco, N. Cannabinoid receptor type 1 (CB1R) expression in limbic brain structures after acute and chronic seizures in a genetic model of epilepsy. Front Behav Neurosci. 2020;14:602258. doi:10.3389/fnbeh.2020.602258. PMID: 33408620; PMCID: PMC7779524.CrossRefGoogle Scholar
Huizenga, MN, Wicker, E, Beck, VC, Forcelli, PA. Anticonvulsant effect of cannabinoid receptor agonists in models of seizures in developing rats. Epilepsia. 2017;58(9):1593–1602.CrossRefGoogle ScholarPubMed
Rosenberg, EC, Tsien, RW, Whalley, BJ, Devinsky, O. Cannabinoids and epilepsy. Neurotherapeutics. 2015;12(4):747–768.CrossRefGoogle ScholarPubMed
Vasincu, A, Rusu, RN, Ababei, DC, et al. Exploring the therapeutic potential of cannabinoid receptor antagonists in inflammation, diabetes mellitus, and obesity. Biomedicines. 2023;11(6):1667. doi:10.3390/biomedi-cines11061667. PMID: 37371762; PMCID: PMC10296259.CrossRefGoogle ScholarPubMed
Manna, SS, Umathe, SN. Involvement of transient receptor potential vanilloid type 1 channels in the pro-convulsant effect of anandamide in pentylenetetrazole-induced seizures. Epilepsy Res. 2012;100(1–2):113–124.CrossRefGoogle ScholarPubMed
Wootten, D, Christopoulos, A, Sexton, PM. Emerging paradigms in GPCR allostery: implications for drug discovery. Nat Rev Drug Discov. 2013;12(8):630–644.CrossRefGoogle ScholarPubMed
Wallace, MJ, Martin, BR, DeLorenzo, RJ. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur J Pharmacol. 2002;452(3):295–301.CrossRefGoogle ScholarPubMed
Gaston, TE, Szaflarski, JP. Cannabis for the treatment of epilepsy: an update. Curr Neurol Neurosci Rep. 2018;18(11):73.CrossRefGoogle ScholarPubMed
Devinsky, O, Marsh, E, Friedman, D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15(3):270–278.CrossRefGoogle ScholarPubMed
O’Connell, BK, Gloss, D, Devinsky, O. Cannabinoids in treatment-resistant epilepsy: a review. Epilepsy Behav. 2017;70:341–348.CrossRefGoogle ScholarPubMed
Moore, RA, Fisher, E, Finn, DP, et al. Cannabinoids, cannabis, and cannabis-based medicines for pain management: an overview of systematic reviews. Pain. 2021;162:S67–S79.CrossRefGoogle ScholarPubMed
Busse, JW, Vankrunkelsven, P, Zeng, L, et al. Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline. BMJ. 2021;374:n2040.CrossRefGoogle ScholarPubMed
Pratt, M, Stevens, A, Thuku, M, et al. Benefits and harms of medical cannabis: a scoping review of systematic reviews. Syst Rev. 2019;8(1):320.CrossRefGoogle ScholarPubMed
Sarris, J, Sinclair, J, Karamacoska, D, Davidson, M, Firth, J. Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. BMC Psychiatry. 2020;20(1):24.CrossRefGoogle ScholarPubMed
Gage, SH, Hickman, M, Zammit, S. Association between cannabis and psychosis: epidemiologic evidence. Biol Psychiatry. 2016;79(7):549–556.CrossRefGoogle ScholarPubMed
Kraan, T, Velthorst, E, Koenders, L, et al. Cannabis use and transition to psychosis in individuals at ultra-high risk: review and meta-analysis. Psychol Med. 2016;46(4):673–681.CrossRefGoogle ScholarPubMed
D’Souza, DC, Perry, E, MacDougall, L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29(8):1558–1572.CrossRefGoogle ScholarPubMed
D’Souza, DC, Abi-Saab, WM, Madonick, S, et al. Delta-9-tetrahydrocannab-inol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. 2005;57(6):594–608.CrossRefGoogle ScholarPubMed
Leweke, FM, Piomelli, D, Pahlisch, F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2:e94.CrossRefGoogle ScholarPubMed
Zuardi, AW, Morais, SL, Guimaraes, FS, Mechoulam, R. Antipsychotic effect of cannabidiol. J Clin Psychiatry. 1995;56(10):485–486.Google ScholarPubMed
Galli, JA, Sawaya, RA, Friedenberg, FK. Cannabinoid hyperemesis syndrome. Curr Drug Abuse Rev. 2011;4(4):241–249.CrossRefGoogle ScholarPubMed
Wallace, EA, Andrews, SE, Garmany, CL, Jelley, MJ. Cannabinoid hyperemesis syndrome: literature review and proposed diagnosis and treatment algorithm. South Med J. 2011;104(9):659–664.CrossRefGoogle ScholarPubMed
Buckley, N, Hansson, S, Harta, G, Mezey, E. Expression of the CB1 and CB2 receptor messenger RNAs during embryonic development in the rat. Neuroscience. 1997;82(4):1131–1149.CrossRefGoogle Scholar
Biegon, A, Kerman, IA. Autoradiographic study of pre- and postnatal distribution of cannabinoid receptors in human brain. Neuroimage. 2001;14(6):1463–1468.CrossRefGoogle ScholarPubMed
Mato, S, Del Olmo, E, Pazos, A. Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain. Eur J Neurosci. 2003;17(9):1747–1754.CrossRefGoogle ScholarPubMed
Fernandez-Ruiz, J, Berrendero, F, Hernandez, ML, Ramos, JA. The endogenous cannabinoid system and brain development. Trends Neurosci. 2000;23(1):14–20.CrossRefGoogle ScholarPubMed
Berrendero, F, Sepe, N, Ramos, JA, Di Marzo, V, Fernandez-Ruiz, JJ. Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. Synapse. 1999;33(3):181–191.3.0.CO;2-R>CrossRefGoogle ScholarPubMed
Maccarrone, M, Guzman, M, Mackie, K, Doherty, P, Harkany, T. Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies. Nat Rev Neurosci. 2014;15(12):786–801.CrossRefGoogle Scholar
Harkany, T, Mackie, K, Doherty, P. Wiring and firing neuronal networks: endocannabinoids take center stage. Curr Opin Neurobiol. 2008;18(3):338–345.CrossRefGoogle ScholarPubMed
Martinez-Pena, AA, Perono, GA, Gritis, SA, et al. The impact of early life exposure to cannabis: the role of the endocannabinoid system. Int J Mol Sci. 2021;22(16):8576.CrossRefGoogle ScholarPubMed
El Marroun, H, Hudziak, JJ, Tiemeier, H, et al. Intrauterine cannabis exposure leads to more aggressive behavior and attention problems in 18-month-old girls. Drug Alcohol Depend. 2011;118(2–3):470–475.CrossRefGoogle ScholarPubMed
Day, NL, Richardson, GA, Goldschmidt, L, et al. Effect of prenatal marijuana exposure on the cognitive development of offspring at age three. Neurotoxicol Teratol. 1994;16(2):169–175.CrossRefGoogle ScholarPubMed
Goldschmidt, L, Richardson, GA, Willford, J, Day, NL. Prenatal marijuana exposure and intelligence test performance at age 6. J Am Acad Child Adolesc Psychiatry. 2008;47(3):254–263.CrossRefGoogle ScholarPubMed
Russo, EB. Cannabis treatments in obstetrics and gynecology: a historical review. J Cannabis Therap. 2002;2(3–4):5–35.CrossRefGoogle Scholar
Polcaro, J, Vettraino, IM. Cannabis in pregnancy and lactation – a review. Missouri Med. 2020;117(5):400–405.Google Scholar
Grant, KS, Conover, E, Chambers, CD. Update on the developmental consequences of cannabis use during pregnancy and lactation. Birth Defects Res. 2020;112(15):1126–1138.CrossRefGoogle ScholarPubMed
Guidance for the Use of Medicinal Cannabis in Australia: Overview. Version 1, December 2017. Australian Government Department of Health, Therapeutic Goods Administration. www.tga.gov.au/sites/default/files/guidance-use-medicinal-cannabis-australia-overview.pdf. Accessed February 25, 2022.Google Scholar
Baker, T, Datta, P, Rewers-Felkins, K, et al. Transfer of inhaled cannabis into human breast milk. Obstetr Gynecol. 2018;131(5):783–788.CrossRefGoogle ScholarPubMed
Moss, MJ, Bushlin, I, Kazmierczak, S, et al. Cannabis use and measurement of cannabinoids in plasma and breast milk of breastfeeding mothers. Pediatr Res. 2021;90(4):861–868.CrossRefGoogle ScholarPubMed
Narayanan, P, Bertrand, K, Waalen, J, et al. The effect of cannabis consumption during lactation on the macronutrient concentrations in breast milk. Breastfeed Med. 2025;20(1):33–41.CrossRefGoogle ScholarPubMed
Jones, RT. Cardiovascular system effects of marijuana. J Clin Pharmacol. 2002;42(S1):58S–63S.CrossRefGoogle ScholarPubMed
Goyal, H, Awad, HH, Ghali, JK. Role of cannabis in cardiovascular disorders. J Thorac Dis. 2017;9(7):2079–2092.CrossRefGoogle ScholarPubMed
Korantzopoulos, P, Liu, T, Papaioannides, D, Li, G, Goudevenos, JA. Atrial fibrillation and marijuana smoking. Int J Clin Pract. 2008;62(2):308–313.CrossRefGoogle ScholarPubMed
Mittleman, MA, Lewis, RA, Maclure, M, Sherwood, JB, Muller, JE. Triggering myocardial infarction by marijuana. Circulation. 2001;103(23):2805–2809.CrossRefGoogle ScholarPubMed
Rumalla, K, Reddy, AY, Mittal, , MK Recreational marijuana use and acute ischemic stroke: a population-based analysis of hospitalized patients in the United States. J Neurol Sci. 2016;364:191–196.CrossRefGoogle Scholar
Thanvi, B, Treadwell, SD. Cannabis and stroke: is there a link? Postgrad Med J. 2009;85(1000):80–83.CrossRefGoogle ScholarPubMed
Wolff, V, Lauer, V, Rouyer, O, et al. Cannabis use, ischemic stroke, and multifocal intracranial vasoconstriction: a prospective study in 48 consecutive young patients. Stroke. 2011;42(6):1778–1780.CrossRefGoogle ScholarPubMed
Memedovich, KA, Dowsett, LE, Spackman, E, Noseworthy, T, Clement, F. The adverse health effects and harms related to marijuana use: an overview review. CMAJ Open. 2018;6(3):E339–E346.CrossRefGoogle ScholarPubMed
Garfield, JB, Lubman, DI, Yucel, M. Anhedonia in substance use disorders: a systematic review of its nature, course and clinical correlates. Aust N Z J Psychiatry. 2014;48(1):36–51.CrossRefGoogle ScholarPubMed
Ganzer, F, Broning, S, Kraft, S, Sack, PM, Thomasius, R. Weighing the evidence: a systematic review on long-term neurocognitive effects of cannabis use in abstinent adolescents and adults. Neuropsychol Rev. 2016;26(2):186–222.CrossRefGoogle ScholarPubMed
Broyd, SJ, van Hell, HH, Beale, C, Yucel, M, Solowij, N. Acute and chronic effects of cannabinoids on human cognition – a systematic review. Biol Psychiatry. 2016;79(7):557–567.CrossRefGoogle ScholarPubMed
Jackson, NJ, Isen, JD, Khoddam, R, et al. Impact of adolescent marijuana use on intelligence: results from two longitudinal twin studies. Proc Natl Acad Sci U S A. 2016;113(5):E500–E508.CrossRefGoogle ScholarPubMed
Yamaori, S, Ebisawa, J, Okushima, Y, Yamamoto, I, Watanabe, K. Potent inhibition of human cytochrome P450 3 A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci. 2011;88(15–16):730–736.CrossRefGoogle ScholarPubMed
Watanabe, K, Yamaori, S, Funahashi, T, Kimura, T, Yamamoto, I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci. 2007;80(15):1415–1419.CrossRefGoogle Scholar
Cascorbi, I. Drug interactions – principles, examples and clinical consequences. Dtsch Arztebl Int. 2012;109(33–34):546–555; quiz 56.Google ScholarPubMed
Sinclair, J, Sinclair, C. Polypharmacy and drug-nutraceutical interactions. In Sarris, J, Wardle, J, eds. Clinical Naturopathy: An Evidence-Based Guide to Practice. Sydney, Australia: Elsevier Australia; 2014:823–838.Google Scholar
Abrams, DI, Couey, P, Shade, SB, Kelly, ME, Benowitz, NL. Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther. 2011;90(6):844–851.CrossRefGoogle ScholarPubMed
Haroutounian, S, Ratz, Y, Ginosar, Y, et al. The effect of medicinal cannabis on pain and quality-of-life outcomes in chronic pain: a prospective open-label study. Clin J Pain. 2016;32(12):1036–1043.CrossRefGoogle ScholarPubMed
Armour, M, Sinclair, J, Noller, G, et al. Illicit cannabis usage as a management strategy in New Zealand women with endometriosis: an online survey. J Womens Health (Larchmt). 2021;30(10):1485–1492. doi:10.1089/jwh.2020.8668. PMID: 33275491.CrossRefGoogle ScholarPubMed
Alsherbiny, MA, Li, CG. Medicinal cannabis-potential drug interactions. Medicines (Basel). 2018;6(1).Google ScholarPubMed
Polson, G, Chung, M., Hirani, S., Le-Short, C. Cannabis drug interactions. In Narouze, SN, ed. Cannabinoids and Pain. Cham: Springer; 2021:93–101.CrossRefGoogle Scholar
Balachandran, P, Elsohly, M, Hill, KP. Cannabidiol interactions with medications, illicit substances, and alcohol: a comprehensive review. J Gen Intern Med. 2021;36(7):2074–2084.CrossRefGoogle ScholarPubMed
Russo, EB. Current therapeutic cannabis controversies and clinical trial design issues. Front Pharmacol. 2016;7:309.CrossRefGoogle ScholarPubMed
Brown, JD. Potential adverse drug events with tetrahydrocannabinol (THC) due to drug-drug interactions. J Clin Med. 2020;9(4):919.CrossRefGoogle ScholarPubMed
Lopera, V, Rodriguez, A, Amariles, P. Clinical relevance of drug interactions with cannabis: a systematic review. J Clin Med. 2022;11(5):1154. doi: 10.3390/jcm11051154. PMID: 35268245PMCID: PMC8911401.CrossRefGoogle ScholarPubMed
Chen, X, Unadkat, JD, Mao, Q. Tetrahydrocannabinol and its major metabolites are not (or are poor) substrates or inhibitors of human p-glycoprotein [ATP-binding cassette (ABC) B1] and breast cancer resistance protein (ABCG2). Drug Metab Dispos. 2021;49(10):910–918.CrossRefGoogle ScholarPubMed
Stott, C, White, L, Wright, S, Wilbraham, D, Guy, G. A phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of rifampicin, ketoconazole, and omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. Springerplus. 2013;2 (1):236.CrossRefGoogle ScholarPubMed
Stout, SM, Cimino, NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014;46(1):86–95.CrossRefGoogle ScholarPubMed

Accessibility standard: WCAG 2.1 AA

Why this information is here

This section outlines the accessibility features of this content - including support for screen readers, full keyboard navigation and high-contrast display options. This may not be relevant for you.

Accessibility Information

The HTML of this chapter complies with version 2.1 of the Web Content Accessibility Guidelines (WCAG), covering newer accessibility requirements and improved user experiences and achieves the intermediate (AA) level of WCAG compliance, covering a wider range of accessibility requirements.

Content Navigation

Table of contents navigation
Allows you to navigate directly to chapters, sections, or non‐text items through a linked table of contents, reducing the need for extensive scrolling.
Index navigation
Provides an interactive index, letting you go straight to where a term or subject appears in the text without manual searching.

Reading Order & Textual Equivalents

Single logical reading order
You will encounter all content (including footnotes, captions, etc.) in a clear, sequential flow, making it easier to follow with assistive tools like screen readers.
Short alternative textual descriptions
You get concise descriptions (for images, charts, or media clips), ensuring you do not miss crucial information when visual or audio elements are not accessible.
Full alternative textual descriptions
You get more than just short alt text: you have comprehensive text equivalents, transcripts, captions, or audio descriptions for substantial non‐text content, which is especially helpful for complex visuals or multimedia.

Visual Accessibility

Use of colour is not sole means of conveying information
You will still understand key ideas or prompts without relying solely on colour, which is especially helpful if you have colour vision deficiencies.

Structural and Technical Features

ARIA roles provided
You gain clarity from ARIA (Accessible Rich Internet Applications) roles and attributes, as they help assistive technologies interpret how each part of the content functions.

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×